Tenet makes key leadership changes

Tenet Healthcare, a Dallas-based healthcare organization and the nation's largest ambulatory platform, has announced several leadership changes. 

First, Daniel Cancelmi, executive vice president and chief financial officer, wil retire at the end of 2023, the company announced. The company is conducting a national search to find his successor, who will be mentored and onboarded by Cancelmi.

“Dan was instrumental in the recent transformation of Tenet’s performance and improvement of the balance sheet,” said Saum Sutaria, MD, CEO of Tenet. “Dan is an inspirational leader with a long legacy at Tenet, starting as a hospital CFO to becoming our corporate CFO. He is a tireless advocate for our people and company. The strength of our finance function at Corporate and across our business units is a testament to Dan’s leadership, operational acumen, and commitment to Tenet.”

Brett Brodnax, president and CEO of Tenet’s United Surgical Partners International (USPI), will also retire at the end of 2023, the company announced. Plus, Andy Johnston was named chief administrative officer of USPI, and he is expected to be promoted after Brodnax steps down. Brodnax has also offered ongoing support in a non-management role after the end of 2023.

“Brett has not just positively shaped USPI, but the overall ambulatory surgery industry. He will always be a distinguished alumnus of the company and a supporter of USPI’s team, community of doctors, and health system partners,” said Sutaria. “Andy is well positioned to step into the USPI president role––he was previously USPI’s chief development officer and chief operating officer of the East Division. I will personally be spending more time with USPI to advance business goals and support the transition.”

Tenet also announced Roger Davis, president and CEO of Conifer Health Solutions, which is also owned by Tenet, will retire at the end of the first quarter of 2023. The company is searching for his replacement. Deepali Narula has been promoted to chief operating officer of Conifer. He formerly served as senior vice president, HRCM Operations. Additionally, Bryan Forry has been promoted to CFO of Conifer. He previously served as controller, hospital operations.

Tenet also announced:

  • Maggie Gill has been promoted to group president, Eastern Group, overseeing Florida, South Carolina and Massachusetts hospital operations.
  • Matthew Stone has been promoted to group president, Central Group, overseeing Central and South Texas, Alabama and Tennessee hospital operations.
  • Nicholas Tejeda has been promoted to group president, Western Group, overseeing West Texas, Northern California and Orange County – Los Angeles hospital operations.

In addition to the leadership changes, Tenet also announced its anticipated adjusted EBITDA will be above its previous guidance of $3.425 billion for 2022.

“Our business units continued to demonstrate effective management capabilities and delivered strong results in the fourth quarter,” Sutaria said. “All three of our business units are expected to produce Adjusted EBITDA excluding grant income that was at or slightly above the mid-point of our guidance. We look forward to providing more details in a few weeks along with sharing plans to support a successful 2023.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.